Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Daling Road 16, Shiyan, Hubei 442000, China.
Department of Cardiology, The Second Hospital of Anhui Medical University, Furong Road 678, Hefei, Anhui 230601, China.
J Diabetes Res. 2023 Apr 15;2023:5891532. doi: 10.1155/2023/5891532. eCollection 2023.
Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disease that has become a growing health problem worldwide, and the dangers of hyperglycemia and its chronic complications have long been considered a goal of diabetes treatment. In recent years, tirzepatide has become the first dual GIP/GLP-1R agonist approved for the treatment of diabetes mellitus in the United States as a new hypoglycemic medicine. Its hypoglycaemic and weight loss effects have been demonstrated in several large clinical trials, and there is also evidence that it has great potential for cardiovascular protection. In addition, the very concept of synthetic peptides opens up many unknown possibilities for tirzepatide. Ongoing trials (NCT04166773) and evidence suggest that it appears to be a promising drug in the areas of NAFLD, renal, and neuroprotection. Based on preclinical studies and clinical trials, the aim of this article is to discuss the latest clinical developments in tirzepatide, to focus on its differences with other incretin therapies, and to suggest future possibilities and mechanisms of tirzepatide therapy.
2 型糖尿病（T2DM）是一种慢性进行性代谢疾病，已成为全球日益严重的健康问题，高血糖及其慢性并发症的危害长期以来一直被认为是糖尿病治疗的目标。近年来，替西帕肽已成为美国批准的第一种用于治疗糖尿病的双重 GIP/GLP-1R 激动剂新型降糖药物。几项大型临床试验已经证明了它的降糖和减肥效果，并且有证据表明它在心血管保护方面具有很大的潜力。此外，合成肽的概念本身为替西帕肽开辟了许多未知的可能性。正在进行的试验（NCT04166773）和证据表明，它在非酒精性脂肪性肝病、肾脏和神经保护等领域似乎是一种很有前途的药物。基于临床前研究和临床试验，本文旨在讨论替西帕肽的最新临床进展，重点讨论其与其他肠促胰岛素治疗的区别，并提出替西帕肽治疗的未来可能性和机制。
